Repare Therapeutics Competitors and Similar CompaniesClear all

Repare Therapeutics's competitors and similar companies include SpringWorks Therapeutics, Agios Pharmaceuticals, Blueprint Medicines and Loxo Oncology.

	Repare Therapeutics Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells.	SpringWorks Therapeutics SpringWorks Therapeutics is dedicated to developing innovative potential new treatments for unserved and underserved patient communities.	Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism.	Blueprint Medicines Blueprint Medicines is a biopharmaceutical company engaged in developing therapies for allergy, inflammation, and oncology/hematology.	Loxo Oncology Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.
Founding Date	Founding Date 2016	Founding Date 2017	Founding Date 2008	Founding Date 2011	Founding Date 2013
Type	Type Public	Type Public	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech drug development oncology platform	Tags Healthcare medical devices medtech	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development life sciences oncology	Tags Healthcare biotech oncology pharma
Locations	Locations Montréal, CA HQ Cambridge, US	Locations Stamford, US HQ Durham, US	Locations Cambridge, US HQ	Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH	Locations Stamford, US HQ Alcobendas, ES Boulder, US New York, US South San Francisco, US
Employees	Employees 129	Employees 568% increase	Employees 53611% increase	Employees 6552% increase	Employees 65610% decrease
Valuation ($)	Valuation ($) 152.4 m	Valuation ($) 2.2 b	Valuation ($) 2.7 b	Valuation ($) 5.3 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $53.5m (FY, 2024)	Revenue (est.) $191.6m (FY, 2024)	Revenue (est.) $54m (FY, 2025)	Revenue (est.) $508.8m (FY, 2024)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $12.6m (FY, 2024)	Cost of goods $6.3m (FY, 2025)	Cost of goods $20.2m (FY, 2024)	Cost of goods N/A
Gross profit	Gross profit $53.5m (FY, 2024)	Gross profit $179m (FY, 2024)	Gross profit $47.7m (FY, 2025)	Gross profit $488.7m (FY, 2024)	Gross profit N/A
Net income	Net income ($84.7m) (FY, 2024)	Net income ($258.1m) (FY, 2024)	Net income ($412.8m) (FY, 2025)	Net income ($67.1m) (FY, 2024)	Net income ($148.9m) (FY, 2017)
Funding
Total funding raised	Total funding raised $ 150.5m	Total funding raised $ 228m	Total funding raised N/A	Total funding raised $ 1.7b	Total funding raised $ 57m